Details of the Drug Reposition

General Information of This Drug (ID: DMDI269)

Drug Name
Docetaxel   DMDI269
Synonyms
EmDOC; TXL; Taxotere; Docetaxel anhydrous; ANX-514; Docetaxel (INN); Docetaxel, Trihydrate; RP-56976; SDP-014; Taxotere (TN); Taxotere(R); XRP-6976L; Docetaxel 114977-28-5; N-debenzoyl-N-Boc-10-deacetyl taxol; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; (2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
8 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Urinary system neoplasm DIS1VI2T N.A. Approved [1]
Prostate adenocarcinoma DISBZYU8 N.A. Approved [1]
Breast carcinoma DIS2UE88 N.A. Approved [1]
Advanced cancer DISAT1Z9 2A00-2F9Z Approved [1]
Leiomyosarcoma DIS6COXM 2B58 Approved [1]
Non-small-cell lung cancer DIS5Y6R9 2C25.Y Approved [1]
Prostate cancer DISF190Y 2C82.0 Approved [1]
Head and neck cancer DISBPSQZ 2D42 Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Indications(s)
2 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Squamous cell carcinoma DISQVIFL 2B60-2D01 Discontinued in Phase 2 [2]
Gynecologic cancer DIST2NIJ 2F33-2F76 Discontinued in Phase 2 [3]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Gastric cancer DISXGOUK 2B72 Investigative [1]
------------------------------------------------------------------------------------

References

1 Docetaxel FDA Label
2 Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy
3 Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer